Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing immunotherapies, has received a milestone payment following dosing the first patient in a clinical trial conducted by AbbVie to evaluate ABBV-303, a solid tumor targeting TriNKET.
 
ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly’s platform technology to enter the clinic, and the first AbbVie-licensed TriNKET drug candidate to enter the clinic. The Phase 1 trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie’s budigalimab (ABBV-181), in solid tumors.
 
“We are delighted that AbbVie has advanced ABBV-303 into the clinic,” said Bill Haney, CEO and Dragonfly co-founder. “AbbVie is a global leader in advancing novel treatments for some of the most complex diseases and a terrific partner. We look forward to continued success and rapid progress with the AbbVie team to advance potential new treatment options for patients.”